| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
Isolinderalactone targets multiple pathways involved in cancer progression and inflammation. It induces apoptosis and cell cycle arrest by modulating pathways such as PI3K/Akt and MAPK. Isolinderalactone suppresses STAT3 signaling through regulation of SOCS3 and miR-30c. It inhibits VEGFR2 activation in endothelial cells, suppressing angiogenic activity. It also exhibits moderate iNOS inhibitory activity with an IC50 of 0.30 μM.
|
|---|---|
| ln Vitro |
In vitro, Isolinderalactone induces apoptosis in MDA-MB-231 breast cancer cells. It suppresses the STAT3 signaling pathway through regulation of SOCS3 and miR-30c. Isolinderalactone suppresses human glioblastoma growth and angiogenic activity through inhibition of VEGFR2 activation in endothelial cells. It exhibits moderate iNOS inhibitory activity with an IC50 of 0.30 μM.
|
| ln Vivo |
In vivo data for Isolinderalactone is not extensively reported in publicly available sources. As a sesquiterpene lactone with anticancer and anti-angiogenic activities in vitro, the compound has potential applications in animal models of cancer. By inhibiting VEGFR2 activation and STAT3 signaling, Isolinderalactone could suppress tumor growth and angiogenesis. However, specific published in vivo efficacy studies are not detailed in the current literature.
|
| Enzyme Assay |
The in vitro apoptosis assay for Isolinderalactone is conducted in MDA-MB-231 breast cancer cells. Cells are treated with varying concentrations of Isolinderalactone, and apoptosis is measured by flow cytometry using Annexin V/PI staining. STAT3 signaling is assessed by Western blotting for phosphorylated STAT3. VEGFR2 inhibition is assessed in endothelial cells by measuring VEGFR2 phosphorylation and angiogenic activity.
|
| Cell Assay |
Cellular assays for Isolinderalactone are conducted in cancer cell lines such as MDA-MB-231 and glioblastoma cells. Cells are treated with varying concentrations of Isolinderalactone. Cell viability and proliferation are measured using standard assays such as MTT or CellTiter-Glo. Apoptosis is assessed by flow cytometry using Annexin V/PI staining. STAT3 and PI3K/Akt signaling are assessed by Western blotting.
|
| Animal Protocol |
In vivo studies for Isolinderalactone would typically involve xenograft mouse models of breast cancer or glioblastoma. The compound would be administered via intraperitoneal or oral routes. Efficacy would be assessed by measuring tumor growth inhibition and angiogenesis. However, specific published in vivo protocols for Isolinderalactone are not available in the current literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Isolinderalactone is not extensively reported. The compound has a molecular weight of 244.28 g/mol and a molecular formula of C15H16O3. It has a density of 1.16±0.1 g/cm³ and a boiling point of 378.8±42.0 °C. As a small molecule, it is expected to have moderate bioavailability. Detailed PK parameters are not available.
|
| Toxicity/Toxicokinetics |
Toxicity data for Isolinderalactone is limited. As a naturally occurring sesquiterpene lactone, it is expected to have a favorable safety profile at low concentrations. However, as with all research compounds, Isolinderalactone is intended for research use only and not for human therapeutic applications. Standard in vitro cytotoxicity assays and in vivo tolerability studies would be required for a complete toxicity assessment.
|
| References |
|
| Additional Infomation |
Isolinderalactone is a benzofuran compound and a metabolite. It has been reported to exist in Neolitsea hiiranensis, Lindera pulcherrima var. hemsleyana, and other organisms with relevant data.
Isolinderalactone (CAS 957-66-4) is a sesquiterpene lactone from Lindera species with anti-inflammatory and anticancer activities. It induces apoptosis, suppresses STAT3 signaling, and inhibits VEGFR2 activation. It has a molecular formula of C15H16O3 and a molecular weight of 244.28 g/mol. Isolinderalactone is a valuable research tool for studying cancer and inflammation. |
| Molecular Formula |
C15H16O3
|
|---|---|
| Molecular Weight |
244.29
|
| Exact Mass |
244.11
|
| CAS # |
957-66-4
|
| PubChem CID |
5318587
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.106
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
18
|
| Complexity |
428
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC1=COC2=C1[C@H]3[C@H](C(=C)C(=O)O3)[C@@](C2)(C)C=C
|
| InChi Key |
VXZIFOKTSURLNL-YDHLFZDLSA-N
|
| InChi Code |
InChI=1S/C15H16O3/c1-5-15(4)6-10-11(8(2)7-17-10)13-12(15)9(3)14(16)18-13/h5,7,12-13H,1,3,6H2,2,4H3/t12-,13-,15-/m0/s1
|
| Chemical Name |
(3aS,4R,8bR)-4-ethenyl-4,8-dimethyl-3-methylidene-5,8b-dihydro-3aH-furo[2,3-e][1]benzofuran-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0935 mL | 20.4675 mL | 40.9350 mL | |
| 5 mM | 0.8187 mL | 4.0935 mL | 8.1870 mL | |
| 10 mM | 0.4093 mL | 2.0467 mL | 4.0935 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
